Protalix BioTherapeutics
PLX
PLX
33 hedge funds and large institutions have $3.86M invested in Protalix BioTherapeutics in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
97% less call options, than puts
Call options by funds: $6K | Put options by funds: $188K
Holders
33
Holding in Top 10
–
Calls
$6K
Puts
$188K
Top Buyers
| 1 | +$139K | |
| 2 | +$17K | |
| 3 | +$7.81K | |
| 4 |
AA
Advisory Alpha
Holland,
Michigan
|
+$2K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.75K |
Top Sellers
| 1 | -$777K | |
| 2 | -$31K | |
| 3 | -$24K | |
| 4 |
Invesco
Atlanta,
Georgia
|
-$11K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10.9K |